

Another Medical Breakthrough ...

Milk Proteins To Treat Lung Patients

MONTREAL, May 6 - Doctors have just reported some unique properties of essential milk proteins that promise to enhance the treatment of major lung disorders, such as chronic obstructive pulmonary disease (COPD) or cystic fibrosis.

Dr. Larry C. Lands of McGill University Health Center in Montreal, Quebec, Canada, presented the findings of a recent double-blind study in which healthy, young volunteers showed a 13% increase in work capacity and peak power after supplementing with a unique whey protein concentrate for three months, relative to a placebo.

"We believe that this is the result of increasing *glutathione* (GSH) production inside cells. GSH is a very important tripeptide that the cells make internally to help fight oxidative stress and in turn, improve muscle performance," said McGill's Dr. Gustavo Bounous, a Career Investigator of the Canadian Medical Research Council and the medical pioneer who discovered these unusual protein precursors. "This is one more application that supports the results we have already seen for Immunocal® in other patients with AIDS or Cancer.

In the Lands' studies, the natural supplement, called Immunocal®, increased levels of glutathione in white blood cells by 35%. This is most remarkable since GSH production is already limited in the cells by feedback inhibition.

"In situations of on going stress like COPD and cystic fibrosis, there is an even greater demand for GSH, compared to normal healthy individuals." Dr. Lands went on to explain at the recent International Conference of the American Lung Association and the recent American Thoracic Society. For this reason, supplementation naturally makes even more sense for lung patients.

Nothing can be more vital for anyone than breathing, but that can be exhausting for patients with lung disease. The same oxygen that sustains life, poses metabolic challenges to human cells that need to mount adequate defense. It appears that increasing GSH is the cells' most effective response. The delivery of Immunocal® provides the only safe, effective and convenient source of the essential precursors.

For millions of North Americans with lung disease, this development offers a new hope on the horizon for better management in the near future. Another clinical trial for patients with cystic fibrosis is currently on the way.